These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781 [TBL] [Abstract][Full Text] [Related]
9. BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients. Zhang M; Zhong X; Shi H; Vanmechelen E; De Vos A; Liu S; Chen B; Mai N; Peng Q; Chen X; Wu Z; Hou L; Zhou H; Ouyang C; Zhang W; Liang W; Dai C; Ning Y J Alzheimers Dis; 2020; 77(1):313-322. PubMed ID: 32804135 [TBL] [Abstract][Full Text] [Related]
11. BACE1: the beta-secretase enzyme in Alzheimer's disease. Vassar R J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696 [TBL] [Abstract][Full Text] [Related]
12. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. Vassar R J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789 [TBL] [Abstract][Full Text] [Related]
13. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093 [TBL] [Abstract][Full Text] [Related]
14. The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease. Shah H; Patel A; Parikh V; Nagani A; Bhimani B; Shah U; Bambharoliya T CNS Neurol Disord Drug Targets; 2020; 19(3):184-194. PubMed ID: 32452328 [TBL] [Abstract][Full Text] [Related]
15. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS. Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639 [TBL] [Abstract][Full Text] [Related]
16. β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. Hampel H; Lista S; Vanmechelen E; Zetterberg H; Giorgi FS; Galgani A; Blennow K; Caraci F; Das B; Yan R; Vergallo A; Alzheimers Res Ther; 2020 Oct; 12(1):130. PubMed ID: 33066807 [TBL] [Abstract][Full Text] [Related]
17. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis. Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065 [TBL] [Abstract][Full Text] [Related]
18. BACE1 as a potential biomarker for Alzheimer's disease. Decourt B; Sabbagh MN J Alzheimers Dis; 2011; 24 Suppl 2(Suppl 2):53-9. PubMed ID: 21403391 [TBL] [Abstract][Full Text] [Related]
19. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582 [TBL] [Abstract][Full Text] [Related]